NFKB1 and breast carcinoma: Therefore, the combination of anti-ErbB2 drugs with NF-kB inhibitors [100] or proteasome inhibitors - which prevent NF-kB activation through inhibition of IkB degradation [103] - may represent a novel and more valuable therapeutic approach to treat RANK-expressing ErbB2-positive breast cancers.